Lupin Limited has achieved a remarkable milestone by securing the No. 1 position globally in the pharmaceutical sector and leading all sectors in India in the S&P Global Corporate Sustainability Assessment 2025. The company announced this achievement on February 26, 2026, highlighting its exceptional performance in environmental, social, and governance (ESG) criteria.

Outstanding Performance in Global ESG Assessment

Lupin attained an impressive score of 91 out of 100 in the comprehensive assessment, establishing itself among the top 1% of companies worldwide. This achievement places the company ahead of both Indian and international peers across all evaluated sectors.

Third Consecutive Yearbook Inclusion

The S&P Global Corporate Sustainability Assessment represents one of the world's most comprehensive ESG benchmarks, evaluating companies on industry-specific economic, environmental, and social criteria. Lupin has earned inclusion in the Sustainability Yearbook 2026 for the third consecutive year, demonstrating consistent excellence in sustainability practices.

The selection criteria for Yearbook inclusion are highly stringent:

• Companies must rank in the top 15% of their industry
• Scores must be within 30% of the industry's top performer
• Of more than 9,200 companies assessed across 59 industries, only 848 earned inclusion

Leadership Commitment to Sustainability

Ramesh Swaminathan, Executive Director, Global CFO and Head of IT and API Plus SBU at Lupin, emphasized the significance of this recognition. He stated that this achievement places Lupin among the topmost global sustainability leaders and reinforces the company's long-term commitment to embedding ESG principles into business strategy.

Strategic ESG Integration

Lupin's recognition reflects its sustained focus on several key areas:

• Responsible business practices across global operations
• Strong governance frameworks
• Environmental stewardship initiatives
• Positive social impact programs
• ESG integration across the entire value chain

The company's performance demonstrates its commitment to creating positive outcomes for patients, communities, and stakeholders worldwide while maintaining leadership in pharmaceutical innovation and manufacturing excellence.

Global Pharmaceutical Leadership

As a global pharmaceutical leader headquartered in Mumbai, India, Lupin distributes products in over 100 markets. The company maintains 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a dedicated workforce of over 24,000 professionals. This extensive infrastructure enables Lupin to maintain its position as a trusted provider of pharmaceutical products while adhering to the highest sustainability standards.

Lupin Limited announced a significant regulatory milestone with the U.S. FDA approval of its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. The pharmaceutical company has immediately commenced commercial launch of the product in the United States market following the regulatory clearance.

Product Details and Market Opportunity

The approved Brivaracetam Oral Solution serves as a bioequivalent alternative to UCB Inc.'s Briviact Oral Solution 10 mg/mL. The medication is specifically indicated for the treatment of partial-onset seizures in patients ranging from 1 month of age and older, addressing a critical therapeutic need in pediatric and adult epilepsy care.

Market Potential and Commercial Impact

The market opportunity for this launch appears substantial, with the reference listed drug Briviact recording estimated annual sales of USD 135 million in the U.S. market. This represents a significant revenue opportunity for Lupin as it enters the competitive epilepsy treatment segment with its generic formulation.

Company Profile and Global Presence

Lupin Limited operates as a global pharmaceutical leader headquartered in Mumbai, India, with distribution networks spanning over 100 international markets. The company maintains a diversified portfolio encompassing branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company has established strong market positions in India and the United States across multiple therapeutic areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health segments. Lupin's commitment to improving patient health outcomes extends through its specialized subsidiaries focusing on diagnostics, digital health solutions, and manufacturing services.